Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers
Alexandra J. van den Broek(The Netherlands Cancer Institute), Marjanka K. Schmidt(University of Cambridge), Emiel J. Rutgers(Oncode Institute), Annegien Broeks, Flora E. van Leeuwen(The Netherlands Cancer Institute), Mike van Beek(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Sten Cornelissen, Laura van ‘t Veer, Pieter J. Westenend(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Maartje J. Hooning(Erasmus MC Cancer Institute), Sabine Siesling(Netherlands Comprehensive Cancer Organisation), Jan J. Jobsen(Medisch Spectrum Twente), Vincent T.H.B.M. Smit(Leiden University Medical Center), Caroline Seynaeve(Radboud University Nijmegen), M.L.G. Janssen‐Heijnen(Eindhoven Cancer Registry), Cees J. Cornelisse
Cited by 104
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k